A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Clinical trial NCT03030612 · COMPLETED

Trial details

NCT number: NCT03030612
Sponsor: OncoVerity, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Leukemia, Myeloid, Acute Myelodysplastic Syndromes

Start date: 2016-12-01
Primary completion: 2022-08-01
Enrollment: 38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.